IMPACT

The day will come when virtually all treatment decisions will take an individual’s DNA profile into account, determined in less than five minutes in any doctor’s office

The companies we invest in all help to address some of the medical needs that are not met by current products or technologies. In other words, they all try to make a difference to patients’ lives. By connecting investors to inventors, our work facilitates the establishment and growth of companies that generate much-needed innovation in healthcare. This is our way of making a small yet valuable contribution to society at large, and fostering life.

 

Over the years, we have invested in more than 75 companies, from start to finish. Excluding debt, these companies have raised capital in excess of €3 billion over their life time. The €400 million of pure equity capital that we have put to work to help start and grow these companies has therefore multiplied more than seven times.


All this start-up and growth capital has helped to develop new diagnoses, new treatments and new devices for indications such as diabetes, cholesterol management, ulcerative colitis, constipation, hematologic indications, pain relief, heart failure, asthma, infectious diseases, cartilage repair and many more. Large numbers of patients have benefitted from these healthcare innovations. Many more may benefit from new products and technologies currently in development by our companies. In the past, many of our companies were acquired by large pharmaceutical, diagnostic or medical device companies, leading to even more capital invested in these products and technologies.


We have put €400 million of pure equity capital to work to help start and grow our companies

Over time, our companies have struck more than 50 strategic partnerships. In total, these partnerships represent a total value in upfront, milestone and royalty payments of approximately €6 billion. In addition, our companies have counted on average of 90 employees. This adds up to a total workforce of some 7,000 highly educated employees. Independent research shows that given the high quality nature of the work performed by these employees, every one of them creates or sustains at least two other jobs in other sectors. Thus, the total workforce supported by our investments exceeds 21,000 employees. 

We believe that the positive impact of our investments on society is large and is exemplified by the many patients that have been or will be treated, diagnosed, monitored or cured, today and in the future, by the companies that we have helped to create and grow.


IMPACT

The day will come when virtually all treatment decisions will take an individual’s DNA profile into account, determined in less than five minutes in any doctor’s office

The companies we invest in all help to address some of the medical needs that are not met by current products or technologies. In other words, they all try to make a difference to patients’ lives. By connecting investors to inventors, our work facilitates the establishment and growth of companies that generate much-needed innovation in healthcare. This is our way of making a small yet valuable contribution to society at large, and fostering life.

 

Over the years, we have invested in more than 75 companies, from start to finish. Excluding debt, these companies have raised capital in excess of €3 billion over their life time. The €400 million of pure equity capital that we have put to work to help start and grow these companies has therefore multiplied more than seven times.


All this start-up and growth capital has helped to develop new diagnoses, new treatments and new devices for indications such as diabetes, cholesterol management, ulcerative colitis, constipation, hematologic indications, pain relief, heart failure, asthma, infectious diseases, cartilage repair and many more. Large numbers of patients have benefitted from these healthcare innovations. Many more may benefit from new products and technologies currently in development by our companies. In the past, many of our companies were acquired by large pharmaceutical, diagnostic or medical device companies, leading to even more capital invested in these products and technologies.


We have put €400 million of pure equity capital to work to help start and grow our companies

Over time, our companies have struck more than 50 strategic partnerships. In total, these partnerships represent a total value in upfront, milestone and royalty payments of approximately €6 billion. In addition, our companies have counted on average of 90 employees. This adds up to a total workforce of some 7,000 highly educated employees. Independent research shows that given the high quality nature of the work performed by these employees, every one of them creates or sustains at least two other jobs in other sectors. Thus, the total workforce supported by our investments exceeds 21,000 employees. 

We believe that the positive impact of our investments on society is large and is exemplified by the many patients that have been or will be treated, diagnosed, monitored or cured, today and in the future, by the companies that we have helped to create and grow.